Étiquette : dépression

Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites

Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites Chun Yang, Jianjun Yang, Ailin Luo and Kenji Hashimoto Translational Psychiatry, 2019, 9, 280 doi : 10.1038/s41398-019-0624-1   Abstract Although the robust antidepressant effects of the N-methyl-D-aspartate receptor (NMDAR) antagonist ketamine in patients with treatment-resistant depression are beyond doubt, the precise molecular and cellular mechanisms underlying its antidepressant effects remain unknown. NMDAR inhibition and the subsequent α-amino-3-hydroxy-5- methyl-4-isoxazolepropionic acid receptor (AMPAR) activation are suggested to play a role in the antidepressant effects of ketamine. Although (R)-ketamine is a less potent NMDAR antagonist than (S)-ketamine, (R)-ketamine has shown more marked and longer-lasting antidepressant-like [...]

Lire la suite

Psychedelics & Cannabis Therapeutics, Martin A. LEE, ProjectCBD.org, 2019

Psychedelics & Cannabis Therapeutics Martin A. Lee  April 17, 2019 https://www.projectcbd.org/culture/psychedelics-cannabis-therapeutics High doses of THC are hallucinogenic, and microdosing LSD is a lot like CBD. These mighty molecules can relieve human suffering and they act through the endocannabinoid system. Although it may not be obvious during these Trump-rattled times, we’re in the midst of a psychedelic revival. There is more interest than ever before in experimenting with LSD, magic mushrooms, ayahuasca, ketamine, and other psychedelic drugs. This renaissance is happening without all the fanfare of the day-glo Sixties, when lysergic acid diethylamide (LSD) escaped from the laboratory and assumed the lead role in an improbable [...]

Lire la suite

Cannabis Use in Adolescence : A Review of Neuroimaging Findings, Yann Chye et al., 2019

Cannabis Use in Adolescence : A Review of Neuroimaging Findings Yann Chye, Erynn Christensen & Murat Yücel Journal of Dual Diagnosis, 2019 Doi : 10.1080/15504263.2019.1636171   ABSTRACT Objective : Shifting policies and widespread acceptance of cannabis for medical and/or recreational purposes have fueled worries of increased cannabis initiation and use in adolescents. In particular, the adolescent period is thought to be associated with an increased susceptibility to the potential harms of repeated cannabis use, due to being a critical period for neuromaturational events in the brain. This review investigates the neuroimaging evidence of brain harms attributable to adolescent cannabis use. Methods : PubMed and Scopus searches were [...]

Lire la suite

La FDA accélère la recherche sur la psilocybine pour les troubles dépressifs majeurs, Aurélien Bernard, 2019

La FDA accélère la recherche sur la psilocybine pour les troubles dépressifs majeurs   Aurélien Bernard Newsweed, 28 novembre 2019 https://www.newsweed.fr/fda-accelere-recherche-psilocybine-depression/     La Food and Drug Administration (FDA) a catégorisé les champignons hallucinogènes en tant que « thérapie révolutionnaire » pour les troubles dépressifs majeurs (MDD), une démarche qui accélérera la recherche de nouveaux médicaments à partir de psilocybine. Cette classification a été créée en 2012 pour encadrer les recherches et le développement produit de médicaments à partir de susbtances ayant un potentiel fort par rapport aux options existantes et pour des patients atteints de maladie grave ou qui met leur vie en danger. La première recherche [...]

Lire la suite

Psychedelics : Where we are now, why we got here, what we must do, Sean J. Belouin & Jack E. Henningfield, 2018

Psychedelics : Where we are now, why we got here, what we must do Sean J. Belouin, Jack E. Henningfield Neuropharmacology, 2018, 142, 7e19 https://doi.org/10.1016/j.neuropharm.2018.02.018 a b s t r a c t The purpose of this commentary is to provide an introduction to this special issue of Neuropharmacology with a historical perspective of psychedelic drug research, their use in psychiatric disorders, research restricting regulatory controls, and their recent emergence as potential breakthrough therapies for several brain-related disorders. It begins with the discovery of lysergic acid diethylamide (LSD) and its promising development as a treatment for several types of mental illnesses during the 1940s. This was [...]

Lire la suite

Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression, Leor Roseman et al., 2018

Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression Leor Roseman, Lysia Demetriou, Matthew B. Wall, David J. Nutt, Robin L. Carhart-Harris Neuropharmacology, 2018, 142, 263e269. https://doi.org/10.1016/j.neuropharm.2017.12.041   Abstract Recent evidence indicates that psilocybin with psychological support may be effective for treating depression. Some studies have found that patients with depression show heightened amygdala responses to fearful faces and there is reliable evidence that treatment with SSRIs attenuates amygdala responses (Ma, 2015). We hypothesised that amygdala responses to emotional faces would be altered post treatment with psilocybin. In this open-label study, 20 individuals diagnosed with moderate to severe, treatment-resistant depression, underwent two separate dosing [...]

Lire la suite

Bibliographie : Kétamine, Dr Christian Sueur, GRECC, novembre 2019

Bibliographie : Kétamine Dr Christian Sueur, GRECC, novembre 2019   Kétamine en Psychiatrie .......................................................1 Kétamine et psychose ...........................................................2 Kétamine et traitement de la dépression ..............................3 Kétamine et prise en charge de l'idéation suicidaire ...........11 Kétamine et prise en charge des troubles psychotraumatiques (PTSD) ......12 Kétamine et addictions .........................................................13 Kétamine et sevrage des opiacés ..........................................14 Kétamine et prise en charge de la douleur ...........................15 Kétamine et prise en charge de la douleur chez l'enfant .....16 Pharmacologie de la kétamine ..............................................17 Neurophysiologie de la kétamine .........................................18 Neurotoxicologie de la kétamine ..........................................20 Kétamine et effets indésirables .............................................20  

Lire la suite

Tribune pour l’expérimentation des psychédéliques en médecine, contre la dépression, l’anxiété, les addictions et pour les soins palliatifs, Société Psychédélique Française, 2019

Tribune pour l’expérimentation des psychédéliques en médecine, contre la dépression, l’anxiété, les addictions et pour les soins palliatifs. Société Psychédélique Française, novembre 2019   D’après l’Organisation mondiale de la santé, une personne sur quatre dans le monde sera affectée à un moment donné de sa vie par des troubles mentaux ou neurologiques. Or, après des décennies d’oubli, nous assistons en dehors de nos frontières à un regain de la recherche clinique psychothérapeutique sur les psychédéliques et au développement de thérapies novatrices impliquant ces substances. Les psychédéliques sont des composés, issus du monde vivant ou de la chimie, provoquant des effets analogues sur le psychisme [...]

Lire la suite

FDA’s Rapid Approval of Esketamine for Severe Depression Questioned, Pauline Anderson, Medscape, 2019

FDA's Rapid Approval of Esketamine for Severe Depression Questioned Pauline Anderson Medscape, November 13, 2019 https://www.medscape.com/viewarticle/921248 While some experts have hailed intranasal esketamine (Spravato, Janssen) as a "game changer" for treatment-resistant depression (TRD), others are concerned over the US Food and Drug Administration's (FDA) rapid approval of the drug. Dr Erick Turner In an editorial published online October 31 in Lancet Psychiatry, Erick H. Turner, MD, who sits on one of the FDA advisory committees that recommended approval of Spravato, said the drug did not meet standard criteria for FDA approval and that there was little evidence to support its safety and efficacy based on data from [...]

Lire la suite

A Chocolate a Day Keeps Depression Away ?, Megan Brooks et al., 2019

A Chocolate a Day Keeps Depression Away ?  Megan Brooks, Laurie Barclay Medscape, 13 / 09 /2019 https://www.medscape.org/viewarticle/917963   Clinical Context Accumulating evidence suggests that dietary factors, such as eating chocolate, may affect depressive symptoms. The potential mood-enhancing properties of chocolate may relate to its orosensory properties, psychoactive ingredients, and activation of neural reward pathways. However, only a few studies have analyzed associations between chocolate consumption and depressive symptoms, with conflicting results. The goal of this analysis was to evaluate associations between chocolate consumption and depressive symptoms in a large, representative sample of US adults enrolled in the US National Health and Nutrition Examination Survey (NHANES) between [...]

Lire la suite